Aims/Background-Telomerase is an enzyme that is expressed in most human neoplasms and is associated with tumour immortality. Determination of the point in neoplastic transformation at which telomerase is expressed may aid the understanding of tumour pathogenesis and progression. Despite numerous reports on telomerase, few studies have investigated its expression in high grade glial tumours. These studies, performed on archival banked, single brain tumour specimens, have shown conflicting results for oligodendrogliomas and unexpectedly negative results for telomerase expression in high grade astrocytomas, with one third to one half of glioblastoma multiformes being negative. Methods-34 rapidly banked glioma specimens taken from patients undergoing gross total surgical resection of their tumours were studied. Telomerase expression was assessed across 3-8 sampled regions from each tumour by the telomeric repeat amplification protocol (TRAP) assay. Matched mirror image tissue samples were taken for histological analysis of tissue adequacy, statistical correlation of telomerase with tumour histological features, Mib-1 (a marker for cell cycling) labelling, and p53 immunohistochemistry. Results-All five well diVerentiated oligodendrogliomas were homogeneously telomerase negative and two of three untreated anaplastic oligodendrogliomas were homogeneously positive. In contrast, 10 of 14 high grade astrocytomas showed heterogeneity for telomerase expression across the multiple regions sampled. All glioblastoma multiformes and two of three anaplastic astrocytomas showed at least one region positive for telomerase. When test samples were individually assessed in both oligodendrogliomas and high grade astrocytomas, telomerase expression was associated with Mib-1 labelling (p < 0.001). For the entire group, telomerase expression was associated with grade of tumour, age of patient, and vascular endothelial proliferation (all p < 0.001). Conclusions-This regional study clarifies that all glioblastoma multiformes are at least focally positive and that telomerase expression correlates with tumour grade in oligodendrogliomas. Homogeneity versus heterogeneity for telomerase expression across multiple regions of oligodendrogliomas versus high grade astrocytomas may provide important preclinical data on the use of antitelomerase agents in these adult glial tumours. (J Clin Pathol 1998;51:284-293) 
Telomerase is a ribonucleoprotein that is critical for the maintainence of continuous cell cycling, with down regulation resulting in cellular senescence. 1 2 In tissues requiring continuous renewal, such as the gut, skin, 3 4 and lymphoid tissues, 5 telomerase continues to be expressed at low levels, while high telomerase expression is found almost exclusively in cells with unchecked proliferation and growthcancer cells. High telomerase levels are nearly always found in solid human tumours, 6 although the grade and stage at which it is expressed for each given tumour type is variable. [7] [8] [9] [10] [11] Telomerase expression occurs in later phases of multistep tumour progression of some classes of tumours, 12 and is especially characteristic of higher grade neoplasms. Information on telomerase expression in the human glial tumours, oligodendrogliomas and high grade astrocytomas (anaplastic astrocytomas and glioblastoma multiformes), has been limited and somewhat conflicting. [13] [14] [15] Langford et al found that 19 of 19 oligodendrogliomas (grade not specified) were positive for telomerase, 13 while our laboratory found negative telomerase expression in two of two low grade (grade 2 of 4; World Health Organisation (WHO) classification) oligodendrogliomas and positive telomerase expression in two of two anaplastic (grade 3 of 4) oligodendrogliomas (a pure oligodendroglioma and a mixed oligodendroglioma-anaplasticastrocytoma),suggesting that telomerase expression correlated with grade in oligodendrogliomas. 14 However, both the studies of Langford and colleagues, 13 our previous study, 14 and a very recently published study by Nakatani and colleagues 15 agreed that a significant percentage of glioblastoma multiformes and anaplastic astrocytomas were negative for telomerase expression, a paradoxical finding in light of their high degree of malignancy and in contrast to the almost uniform telomerase positivity of high grade systemic tumours. Using archivally banked, single tissue samples from each tumour, only 38 of 52 glioblastoma multiformes in the study of Langford and colleagues, 13 10 of 19 glioblastoma multiformes in our previous study, 14 and 12 of 20 glioblastoma multiformes in the study of Nakatani and colleagues 15 were telomerase positive.
In this study, we used prospectively collected, gross total resection specimens obtained over the past 18 months from our institution to determine whether sampling of multiple regions throughout oligodendrogliomas and high grade astrocytomas, coupled with careful banking techniques and histological assessment of the adequacy of banked tissue, could clarify some of these conflicting and/or unexplained results. We hypothesized that, given the relative homogeneity versus heterogeneity of histological features in oligodendrogliomas versus high grade astrocytomas, such patterns might extend to telomerase expression across multiple regions in these tumours. We also sought to correlate telomerase expression with the pertinent histological features for each type of tumour, as well as with immunostaining for a cell cycle marker, Mib-1, using an antibody that stains a nuclear antigen which is expressed throughout active phases of the cell cycle (all phases except G 0 ). In high grade astrocytomas (glioblastoma multiformes/anaplastic astrocytomas) we also correlated telomerase expression with protein immunohistochemistry for p53, via the well characterised D07 antibody. Few previous studies have undertaken detailed analyses of comparison between telomerase expression and Mib-1 or p53 expression, and virtually none have correlated histological features relevant to tumour type with telomerase.
Materials and methods

CRITERIA FOR PATIENT INCLUSION
Only patients who had undergone large, gross total resections of their neoplasms were eligible for the study. All but four patients were operated via stereotactic volumetric resection to achieve gross total resection. Because of concerns about accurate grading, glioma patients with single tissue samples or multiple stereotactic biopsies were not included in this study, even though this considerably limited the number of specimens available for analysis over the year and a half study period. Given the study design of obtaining multiple regional samples from each large resection specimen, these tissues represented uniquely banked specimens unavailable from national tumour tissue banks.
PATIENT POPULATION
Ten oligodendroglioma patients met the criteria for study. They ranged in age from 27 to 52 years and included eight women and two men. Eight of 10 patients had primary, untreated oligodendrogliomas. All five of the well diVerentiated oligodendrogliomas were untreated, whereas three of the five anaplastic oligodendrogliomas were untreated. The two anaplastic oligodendrogliomas were treated with both chemotherapy and cranial irradiation (table 1). All but one patient (oligodendroglioma case 9) are currently alive. Fourteen high grade astrocytoma patients met criteria for inclusion in the study, including 11 glioblastoma multiformes and three anaplastic astrocytomas. Patients ranged in age from 36 to 71 years, and included eight men and six women. Eight of 11 glioblastoma multiformes were untreated and all three anaplastic astrocytomas were untreated. The three treated glioblastoma multiformes received both chemotherapy and cranial irradiation (table 2). All but five patients (glioblastoma multiforme patients 1, 2, 4, 5, and 9) are currently alive.
HANDLING OF TISSUE SPECIMENS
All tumour tissue samples were obtained rapidly from resection specimens, within 15 minutes of surgical tissue removal. Tissue samples were taken from viable areas of tumour, avoiding areas of gross necrosis, especially in patients treated with radio-or chemotherapy. Three to seven anatomically separate areas of tumour tissue were sampled from each resection specimen, with the number of regional specimens taken from each case being determined by the volume of resected tissue available. Tissue was immediately snap frozen in a dry ice/ethanol mixture and stored at −70°C.
GRADING OF TUMOURS
Grading of tumours was performed on the formalin fixed, paraYn wax embedded sections, cut at 4 µm and stained with hematoxylin and eosin. Both the adjacent tissue samples matched to the frozen tissue, as well as additional tissues submitted in toto from the resection specimens, were used for grading. Grading criteria for oligodendrogliomas divided the tumours into anaplastic versus well diVerentiated tumours and required the presence of increased mitotic activity and nuclear anaplasia in anaplastic variants (grade 3 of 4) and the absence of such features in well diVerentiated (grade 2 of 4) variants. In keeping with WHO criteria, 16 grade 1, on the four tiered scale, was not used for oligodendrogliomas. The presence of vascular endothelial proliferation and/or necrosis was not required for an anaplastic tumour (grade 3). Each slide and section was assessed for the presence or absence of tumour necrosis, microcysts, gemistocytes, calcification, degree of cellularity, and nuclear anaplasia, with criteria as outlined in table 1. Nuclear anaplasia was defined as the presence of large, hyperchromatic nuclei with prominent nucleoli but not necessarily irregular, pleomorphic nuclear shape. All mitoses were counted by the same neuropathologist (BKD) to eliminate inter-observer variability. For grading and classification of anaplastic astrocytomas and glioblastoma multiformes, the WHO system was used, 16 as modified by Burger and colleagues 17 and Nelson and colleagues. 18 This defines glioblastoma multiformes as astrocytomas that possess cytological atypia, mitotic activity, usually vascular endothelial proliferation, and necrosis. By definition, anaplastic astrocytomas had cytological atypia and mitotic activity, but no necrosis. Histological features pertinent to high grade astrocytomas were assessed including necrosis, lymphocytic inflammation, gemistocytic features, and vascular endothelial proliferation. In addition, percentage of necrosis in each regional sample was recorded to clarify further whether extremely necrotic specimens might be more likely to show negative telomerase expression.
Mib-1 ASSESSMENT Mib-1 assessment was performed on corresponding mirror image paraYn wax sections using the monoclonal Mib-1 antibody, -Ki-67 (Immunotech Inc, Westbrook, Massachusetts, USA), and the indirect immunoperoxidase technique/avidin-biotin method following microwave treatment. In each case, 1000 cells were manually counted in the most heavily labelled areas and positive nuclear labelling for labelled tumour nuclei was scored (without regard to staining intensity) as percentage of positive tumour nuclei. All actual Mib-1 scoring was performed by a single neuropathologist (BKD) to ensure standardisation of assessment and to reduce inter-observer variability, although confirmation of the general accuracy of the Mib-1 values was carried out independently by the second neuropathologist (CIS). Low Mib-1 labelling was considered to be <5.0%, intermediate labelling index was defined as 5.1-10.9% and high labelling index was >11.0% positive cells. Confidence intervals of 95% were calculated for each case.
IMMUNOHISTOCHEMICAL LOCALISATION OF p53 p53 immunohistochemistry used an anti-p53 antibody (D07, Biogenex, San Ramon, California, USA) which recognises both mutant and wild-type p53. The p53 immunohistochemistry was scored semi-quantitatively with estimates of 0%, <1%, 1-10%, 10-30%, 30-60%, or >60% ranges of positively labelled nuclei.
TELOMERIC REPEAT AMPLIFICATION PROTOCOL (TRAP ASSAY) Frozen tissue blocks (10-50 mg) were washed in 200 ml ice cold wash buVer (10 mM Hepes-KOH, pH 7.5, 1.5 mM MgCl 2 , 10 mM KCl, 1 mM dithiothreitol), resuspended in 20-100 ml ice cold lysis buVer (10 mM Tris-HCl, pH 7.5, 1 mM MgCl 2 , 1 mM EGTA, 0.1 mM phenylmethylsulfonyl fluoride, 5 mM betamercaptoethanol, 0.5% CHAPS, 10% glycerol), and homogenised for five minutes using a disposable hand held homogeniser. The cellular suspension was incubated on ice for 30 minutes and then centrifuged for 30 minutes at 21 000 g at 4°C. The supernatant was removed and quick frozen in an ethanol/dry ice bath. The TRAP assay was performed as described by Kim and colleagues, 6 and protein concentrations were standardised. 19 As a telomerase positive control, an enzyme extract from either HEC-1A cells, an endometrial carcinoma cell line, or HeLa cells, a cervical epitheloid carcinoma cell line (both procured from American Type Culture Collection, Rockville, Maryland, USA), was included in each assay. Negative controls included RNase pretreatment of the tissue extracts, as well as a reagent control without tissue extracts. In addition, PCR inhibitors were ruled out by amplification of an internal 150 base pair (bp) control template. 20 Electrophoresis of the TRAP assay products was performed on a 15% nondenaturing polyacrylamide gel at 50 V/cm. Following electrophoresis, the gels were dried with heat under vacuum and processed for autoradiography. Gels were exposed for 18-65 hours and again for seven days at −70°C. Positive results were defined as multiple consecutive (more than three) six nucleotide repeat bands for each lane, following seven days exposure. A single band, consistent with a size of ∼ 46 bp, was considered to be a primer-dimer artifact and was not considered positive.
SELECTION OF PATIENT GROUPS FOR TELOMERASE
CORRELATION
Statistical association for the entire glioma study group was made for comparison of telomerase with grade of tumour, Mib-1 labelling index, vascular endothelial proliferation, and age of patient. For high grade astrocytomas and oligodendrogliomas, "untreated" patient groups within each tumour category were analysed separately from the "untreated + treated" group. This separation was based on our observation in treated oligodendrogliomas that the matched, adjacent tissue sections taken for histological analysis represented infiltrating edges of tumour that were hypocellular and possibly not representative of the tumour as a whole (see below). Our previous study had also noted that specimens from the infiltrating edges of gliomas might give falsely negative results.
14 A similar observation of sample discordance in treated versus untreated high grade astrocytomas was not made; specifically, none of the treated high grade astrocytomas were sampled from the infiltrating edge as assessed on the matched histological specimen. However, groups were analysed separately in high grade astrocytomas to maintain uniformity of statistical analysis.
STATISTICAL METHODOLOGY
The statistical significance of telomerase activity relative to the determination of gender, treatment status, tumour type, and tumour histological diagnosis was determined using Fisher's exact test. 21 22 Association between telomerase expression, histological features, and Mib-1 labelling was undertaken using univariate analyses for patient and tumour summary data, as well as the generalized estimating equation for tumour specimen data. 23 Statistical significance of Mib-1 variability was determined by the use of Bartlett's test for homogeneity of variance. 24 Association between the Mib-1 labelling index and telomerase was also determined using the Wilcoxon rank sum test, a nonparametric equivalent to the two sample t-test. 25 
Results
ENTIRE GLIOMA STUDY GROUP
Strong statistical relevance (p < 0.001 for each) was found in both the "untreated" and the "untreated + treated" groups when correlating telomerase expression with grade of tumour, Mib-1 labelling index, or age of patient; moderate relevance was found when correlating telomerase expression with vascular endothelial proliferation in the "untreated + treated" group (p = 0.035), but strong statistical relevance was found when correlating telomerase expression with vascular dndothelial proliferation in the "treated" group (p<0.001) (table 3).
OLIGODENDROGLIOMAS
Telomerase activity was uniform across multiple regions of the oligodendrogliomas analysed, with all but one of the ten tumours (oligodendroglioma case 8) homogeneously positive or negative for expression (figs 1 and 2; table 1). Negative telomerase expression was seen in five well diVerentiated tumours with low cell density, little or no nuclear anaplasia, and low mitotic counts as assessed across mul- [6] [7] [8] showed almost all regions with positive telomerase expression (fig 4) . These tumours had Mib-1 labelling indices with wide variance, ranging from 1.9 to 29.2, although all three untreated oligodendrogliomas had at least one area with a high Mib-1 labelling index (>11.0%) (table 1). Both treated anaplastic oligodendrogliomas (cases 9 and 10) showed that tumour was present in the corresponding adjacent mirror image tissue sections taken for tissue adequacy, but in small amounts, (especially oligodendroglioma case 9) and that the tissues were taken from the relatively less cellular, infiltrating edges of the tumour. Both treated anaplastic oligodendrogliomas were homogeneously negative for telomerase. No significant statistical relationship was found between Mib-1 and telomerase expression when either untreated or the whole oligodendroglioma cohort was analysed. However, when test samples were assessed individually, a strong association was found between Mib-1 and telomerase expression. No relationship was found between the presence or absence of microcysts, gemistocytes, or vascular endothelial proliferation and telomerase expression when either the entire oligodendroglioma group or the untreated cases only were analysed (table 3) . Telomerase expression was noted in anaplastic oligodendrogliomas whether or not necrosis was absent or vascular proliferation was very focal or absent.
HIGH GRADE ASTROCYTOMAS
Of the 11 glioblastoma multiformes analysed, all showed at least one region positive for telomerase expression (table 2) . However, only three of the patients (cases 4, 8, and 10) (table 2) showed homogeneously positive telomerase expression across all samples assessed. Weakly positive results, defined as three or more bands on the gel visible only at a seven day exposure (that is, +/− results in table 2) or completely negative results were present in at least one region in eight of 11 glioblastoma multiformes studied (figs 5 and 6). Negative telomerase expression could not be accounted for by a high percentage of necrosis in the specimen, as assessed on the adjacent, mirror image specimen taken for histology. Only two of the three anaplastic astrocytomas showed definite positive telomerase expression in one of seven (case 12; table 2) and four of seven (case 13; table 2) regions studied. The third anaplastic astrocytomas (case 14; table 2) was completely negative for telomerase. Although the number of anaplastic astrocytomas in this study was small, an interesting association between the number of regions showing histological anaplasia and regions positive for telomerase expression was observed.
We analysed the glioblastoma multiformes/ anaplastic astrocytoma group separately for all patients versus untreated patients; however, unlike the two treated oligodendroglioma cases, the tissue specimens from the treated glioblastoma multiformes patients were all predominately sampled in areas of high cell density and not the hypocellular, infiltrating edge of the neoplasm. As noted in table 2, previous treatment did not aVect telomerase expression. A strong statistical association was found between Mib-1 and telomerase expression when either treated and untreated cases or untreated cases alone were analysed (table 3) .
Decreased inflammation and positive telomerase expression showed significant correlation for both the high grade astrocytoma group as a whole and for the untreated cases (table 3 ). An inverse relation was also found between gemistocytic prominence and telomerase expression for both the whole glioblastoma multiformes/ anaplastic astrocytoma group and the untreated high grade astrocytoma group; the tumour with the most prominent lymphocytic inflammation and gemistocytic features also had one of the lowest mean Mib-1 labelling scores of the glioblastoma multiformes (case 2; table 2). A relation between vascular endothelial proliferation and telomerase expression for both the high grade astrocytoma group as a whole and for untreated patients only was noted. However, when this was adjusted for the fact that no anaplastic astrocytoma demonstrated vascular endothelial proliferation, no relation between telomerase and vascular endothelial proliferation remained (table 3) .
REGIONAL DIFFERENCES IN p53
IMMUNOHISTOCHEMISTRY AND RELATION TO TELOMERASE EXPRESSION Three of 11 glioblastoma multiformes showed regions with positivity in 10-30% of cells or more; there was slight regional variation for p53 immunoreactivity within each case (cases 5, 7, and 10; table 2). The strongest p53 immunoreactivity was noted in case 10, the glioblastoma multiforme with sarcomatous transformation, and this case was homogeneously telomerase positive. However, two of the anaplastic astrocytomas (cases 12 and 14) also showed strong p53 immunoreactivity, but nearly opposite (mostly or completely negative) telomerase expression. Analysis between p53 immunoreactivity and telomerase expression did not reach statistical significance for either the untreated tumours or the glioblastoma multiformes/anaplastic astrocytoma group as a whole (table 3) .
Discussion
The first objective of this study was to explain the paradoxical finding of the absence of telomerase expression in one half to one third of glioblastoma multiformes cases previously tested by TRAP analysis. [13] [14] [15] Second, we were interested in whether increasing telomerase expression was associated with increasing grade of tumour, as we had previously suggested, 14 and whether telomerase expression could be associated with Mib-1 labelling or histological features relevant to specific tumour type. Few previous studies have detailed correlation of relevant histological features with telomerase expression in tumours. The results of this study show that: (1) telomerase expression is found in all glioblastoma multiformes, albeit sometimes focally; (2) telomerase expression is associated with grade of tumour in both oligodendrogliomas (p < 0.001) and high grade astrocytomas (glioblastoma multiformes/anaplastic astrocytomas) (p < 0.001); and (3) telomerase expression is associated with Mib-1 labelling (p < 0.001), age of patient (p < 0.001), and vascular endothelial proliferation (p = 0.035) in the study group as a whole. Telomerase expression was more homogeneous throughout multiple regional samples in untreated oligodendrogliomas than in the high grade astrocytoma group, where only four of 14 glioblastoma multiformes/anaplastic astrocytomas showed homogeneity of telomerase expression in the multiple regional tumour samples (p < 0.001).
Our original hypothesis for the first part of this study was that glioblastoma multiformes are highly heterogeneous tumours with protean gross and microscopic features and that this variability might extend to expression of tumour markers, including telomerase. This study demonstrates definitively that variations in telomerase expression exist from region to region within glioblastoma multiformes, suggesting that analysing only a single specimen from a glioblastoma multiformes might yield a nonrepresentative result. Our study explains, at least in part, the previously puzzling finding that the highest grade glial neoplasms, the glioblastoma multiformes, showed negative telomerase expression in one half to one third of cases studied, despite its nearly ubiquitous presence in other high grade neoplasms from other organ systems. [13] [14] [15] A second objective of this study for high grade astrocytomas was to attempt to associate regional telomerase activity with common histological features found in these tumours, as well as with Mib-1 and p53 immunohistochemistry. No association between telomerase expression and the degree of necrosis in the tumour was noted. Specifically, a high percentage of necrosis in the tumour sample did not account for negative telomerase expression in this study, confirming our earlier findings. 14 We also examined lymphocytic inflammation in the tumour in relation to telomerase expression and found statistical association with decreased lymphocytic inflammation and increased telomerase expression. Although we originally hypothesised a possible relation between increased lymphocytic inflammation and positive telomerase expression in a tumour, because of the known positivity of non-neoplastic lymphocytes for telomerase (albeit low levels), 26 this was not the case. The likely explanation for this statistically relevant finding is that greatly increased lymphocytic inflammation is common in gemistocytic astrocytic tumours that also show low Mib-1 labelling indices, 27 with which telomerase levels inversely correlated.
Because at least low levels of telomerase can be found in non-neoplastic tissues that require constant renewal, 28 29 and an association be-tween Mib-1 labelling and telomerase expression has been documented in other cancers, 30 we investigated whether telomerase expression might be associated with Mib-1 labelling in gliomas. Strong statistical association could be seen between Mib-1 labelling and positive telomerase expression in this study for high grade astrocytomas. A recent study by Sallinen and colleagues 31 has also shown association between Mib-1 labelling and telomerase expression in astrocytomas, as well as heterogeneity of expression, using in situ hybridisation for telomerase RNA.
Our attempt to correlate p53 protein immunohistochemistry with telomerase expression in high grade astrocytomas was based on the known high frequency of p53 mutations in astrocytic tumours and the suggestion that clonal expansion of p53 mutated cells occurs in the malignant progression of astrocytomas, 32 although Louis has suggested that p53 protein accumulation can occur in high grade astrocytomas for reasons other than p53 mutation. 33 We found no relation between telomerase expression and p53 protein immunohistochemistry in high grade astrocytomas in this study. The application of hTR in situ hybridisation will make it possible to readdress the question of p53 protein accumulation and telomerase expression at the individual cell level.
A third objective of this study was the investigation of whether telomerase expression could be associated with grade of tumour, histological features, and Mib-1 labelling in oligodendrogliomas. In general, low grade oligodendrogliomas were telomerase negative and untreated anaplastic oligodendrogliomas were telomerase positive, confirming our initial findings that telomerase expression is associated with tumour grade.
14 This finding may contrast with the original study by Langford et al, who found 19 of 19 oligodendrogliomas (grade not designated) positive. 13 A strong statistical association was noted between grade of oligodendroglioma, as defined in our current study, and telomerase expression.
Although most neuropathologists divide oligodendrogliomas into well diVerentiated and anaplastic variants, the criteria for grading oligodendrogliomas are less precise than those used for high grade astrocytomas. Hence, we analysed a greater number of potentially relevant [34] [35] [36] [37] histological features in oligodendrogliomas than in high grade astrocytomas, and examined this correlation with telomerase expression. Our study found no association between telomerase expression and most of these debated histological features in the untreated oligodendrogliomas that we analysed, including microcyst formation, high cell density, gemistocytes, or mitoses (table 3) . Only correlation between necrosis and telomerase expression in this group reached statistical significance.
We were also interested in associating telomerase with Mib-1 labelling in oligodendrogliomas because several investigators 38 39 had concluded that the Mib-1 labelling index has prognostic significance for oligodendrogliomas independent of other prognostic indicators such as patient age, site of tumour, and grade. However, SchiVer and colleagues 37 noted that although a shorter survival was found for oligodendrogliomas with Mib-1 labelling indices of greater than 15%, there was a large overlap between the Mib-1 labelling index ranges for "benign" and "malignant" oligodendrogliomas. They concluded that Mib-1 analysis was a useful prognostic tool, but not of absolute reliability in individual cases, a conclusion which we agree with. In our current study, when within patient variability was accounted for, no association was found between Mib-1 labelling and telomerase expression when either untreated oligodendrogliomas alone or the whole oligodendrogliomas group was analysed. However, when test samples were assessed individually, a strong association was found between the Mib-1 labelling index and telomerase expression. From this study, telomerase expression in oligodendrogliomas appears to be at least as useful as Mib-1 labelling or histological assessment in defining two groups of oligodendrogliomas.
In conclusion, this study has shown that: (1) telomerase expression is strongly associated with grade of tumour in both oligodendrogliomas and high grade astrocytomas; (2) telomerase expression is strongly associated with Mib-1 labelling, age of patient, grade of tumour, and vascular endothelial proliferation in the glioma study group as a whole; and (3) all glioblastoma multiformes tested to date are, in fact, at least focally telomerase positive. Future studies will investigate the usefulness telomerase expression as an adjunct to the grading of oligodendrogliomas. 
